腹膜がん(Peritoneal Cancer)の治療薬パイプライン動向(2015年上半期版)

【英語タイトル】Peritoneal Cancer - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6120IDB)・商品コード:GMDHC6120IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年1月22日
・ページ数:439
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における腹膜がん(Peritoneal Cancer)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・腹膜がん(Peritoneal Cancer)の概要
・腹膜がん(Peritoneal Cancer)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・腹膜がん(Peritoneal Cancer)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・腹膜がん(Peritoneal Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・腹膜がん(Peritoneal Cancer)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Peritoneal Cancer – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Peritoneal Cancer – Pipeline Review, H1 2015’, provides an overview of the Peritoneal Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Peritoneal Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Peritoneal Cancer – Overview 12
Pipeline Products for Peritoneal Cancer – Comparative Analysis 13
Peritoneal Cancer – Therapeutics under Development by Companies 14
Peritoneal Cancer – Therapeutics under Investigation by Universities/Institutes 19
Peritoneal Cancer – Pipeline Products Glance 20
Late Stage Products 20
Clinical Stage Products 21
Early Stage Products 22
Peritoneal Cancer – Products under Development by Companies 23
Peritoneal Cancer – Products under Investigation by Universities/Institutes 28
Peritoneal Cancer – Companies Involved in Therapeutics Development 29
AbbVie Inc. 29
Acceleron Pharma, Inc. 30
Adaptimmune Limited 31
Advanced Accelerator Applications SA 32
Amgen Inc. 33
Astellas Pharma Inc. 34
Astex Pharmaceuticals, Inc. 35
AstraZeneca PLC 36
Basilea Pharmaceutica AG 37
Bayer AG 38
BioMarin Pharmaceutical Inc. 39
Bionomics Limited 40
Boehringer Ingelheim GmbH 41
Celldex Therapeutics, Inc. 42
Celsion Corporation 43
Cerulean Pharma, Inc. 44
Clovis Oncology, Inc. 45
Corcept Therapeutics Incorporated 46
CritiTech, Inc. 47
CTI BioPharma Corp. 48
Eli Lilly and Company 49
Exelixis, Inc. 50
F. Hoffmann-La Roche Ltd. 51
Galena Biopharma, Inc. 52
Genelux Corporation 53
Genentech, Inc. 54
GlaxoSmithKline plc 55
Glycotope GmbH 56
Hemispherx Biopharma, Inc. 57
ImmunoGen, Inc. 58
Immunotope, Inc. 59
Immunovaccine, Inc. 60
Johnson & Johnson 61
Lee’s Pharmaceutical Holdings Limited 62
MabVax Therapeutics Holdings, Inc. 63
MedImmune, LLC 64
Merck & Co., Inc. 65
Merrimack Pharmaceuticals, Inc. 66
NeoStem, Inc. 67
Novartis AG 68
Neovii Biotech GmbH 69
Oasmia Pharmaceutical AB 70
OBI Pharma, Inc. 71
Oncolytics Biotech Inc. 72
OncoMed Pharmaceuticals, Inc. 73
Onxeo SA 74
Oxford BioMedica plc 75
OXiGENE, Inc. 76
Pharma Mar, S.A. 77
Pharmacyclics, Inc. 78
PsiOxus Therapeutics, Ltd. 79
Recepta Biopharma S.A. 80
Sanofi Pasteur SA 81
Synta Pharmaceuticals Corp. 82
Takeda Oncology 83
TapImmune Inc. 84
TetraLogic Pharmaceuticals 85
TRACON Pharmaceuticals, Inc. 86
VentiRx Pharmaceuticals, Inc. 87
Peritoneal Cancer – Therapeutics Assessment 88
Assessment by Monotherapy Products 88
Assessment by Target 89
Assessment by Mechanism of Action 94
Assessment by Route of Administration 98
Assessment by Molecule Type 100
Drug Profiles 102
²¹²Pb-TCMC-Trastuzumab – Drug Profile 102
abexinostat hydrochloride – Drug Profile 104
abiraterone acetate – Drug Profile 106
ABT-767 – Drug Profile 109
alisertib – Drug Profile 110
anetumab ravtansine – Drug Profile 114
AZD-1775 – Drug Profile 116
AZD-2014 – Drug Profile 118
AZD-5363 – Drug Profile 120
BAL-101553 – Drug Profile 122
belinostat – Drug Profile 123
bevacizumab – Drug Profile 126
binimetinib – Drug Profile 131
birinapant – Drug Profile 135
BNC-105P – Drug Profile 138
cabozantinib s-malate – Drug Profile 140
Cancer Stem Cell Therapy – Drug Profile 143
catumaxomab – Drug Profile 144
CDX-1401 – Drug Profile 146
Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology – Drug Profile 148
Cell Therapy to Target WT1 for Cancer – Drug Profile 150
CRLX-101 – Drug Profile 151
dalantercept – Drug Profile 153
demcizumab – Drug Profile 155
Dendritic Cell Therapy for Cancer – Drug Profile 159
Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer – Drug Profile 160
DMUC-4064A – Drug Profile 161
DPX-Survivac – Drug Profile 162
EGEN-001 – Drug Profile 165
elesclomol – Drug Profile 167
enadenotucirev – Drug Profile 169
erismodegib – Drug Profile 171
fosbretabulin tromethamine – Drug Profile 174
GALE-301 – Drug Profile 178
ganetespib – Drug Profile 180
gimatecan – Drug Profile 184
GLONC-1 – Drug Profile 186
guadecitabine – Drug Profile 189
IMGN-853 – Drug Profile 192
IMT-1012 – Drug Profile 193
ipafricept – Drug Profile 194
LCL-161 – Drug Profile 195
lifastuzumab vedotin – Drug Profile 197
linsitinib – Drug Profile 199
LY-2606368 – Drug Profile 201
MesoCART – Drug Profile 202
mifepristone – Drug Profile 203
MK-2206 – Drug Profile 205
Monoclonal Antibody Conjugate to Target B7-H3 for Cancer – Drug Profile 208
motolimod – Drug Profile 209
MV-NIS – Drug Profile 211
nintedanib – Drug Profile 213
NSC-748933 – Drug Profile 217
OBI-822/821 – Drug Profile 218
olaratumab – Drug Profile 220
paclitaxel – Drug Profile 222
paclitaxel – Drug Profile 224
paclitaxel poliglumex – Drug Profile 225
PankoMab-GEX – Drug Profile 229
pazopanib hydrochloride – Drug Profile 230
pelareorep – Drug Profile 235
ralimetinib mesylate – Drug Profile 240
ramucirumab – Drug Profile 241
RebmAb-100 – Drug Profile 246
regorafenib – Drug Profile 248
rintatolimod – Drug Profile 251
rucaparib phosphate – Drug Profile 252
selumetinib sulfate – Drug Profile 255
seribantumab – Drug Profile 258
SG-2000 – Drug Profile 260
sofituzumab vedotin – Drug Profile 262
sorafenib tosylate – Drug Profile 263
talazoparib – Drug Profile 267
Theranean – Drug Profile 269
TPIV-200 – Drug Profile 270
trabectedin – Drug Profile 272
TRC-105 – Drug Profile 275
trebananib – Drug Profile 277
TroVax – Drug Profile 280
Vaccine for Oncology – Drug Profile 283
Vaccine to Target Carcinoembryonic Antigen for Oncology – Drug Profile 284
vCP-2292 – Drug Profile 285
X-82 – Drug Profile 286
Peritoneal Cancer – Recent Pipeline Updates 287
Peritoneal Cancer – Dormant Projects 428
Peritoneal Cancer – Discontinued Products 429
Peritoneal Cancer – Product Development Milestones 430
Featured News & Press Releases 430
Appendix 433
Methodology 433
Coverage 433
Secondary Research 433
Primary Research 433
Expert Panel Validation 433
Contact Us 434
Disclaimer 434

[List of Tables]
Number of Products under Development for Peritoneal Cancer, H1 2015 17
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 20
Number of Products under Development by Companies, H1 2015 (Contd..1) 21
Number of Products under Development by Companies, H1 2015 (Contd..2) 22
Number of Products under Development by Companies, H1 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H1 2015 24
Comparative Analysis by Late Stage Development, H1 2015 25
Comparative Analysis by Clinical Stage Development, H1 2015 26
Comparative Analysis by Early Stage Development, H1 2015 27
Products under Development by Companies, H1 2015 28
Products under Development by Companies, H1 2015 (Contd..1) 29
Products under Development by Companies, H1 2015 (Contd..2) 30
Products under Development by Companies, H1 2015 (Contd..3) 31
Products under Development by Companies, H1 2015 (Contd..4) 32
Products under Investigation by Universities/Institutes, H1 2015 33
Peritoneal Cancer - Pipeline by AbbVie Inc., H1 2015 34
Peritoneal Cancer - Pipeline by Acceleron Pharma, Inc., H1 2015 35
Peritoneal Cancer - Pipeline by Adaptimmune Limited, H1 2015 36
Peritoneal Cancer - Pipeline by Advanced Accelerator Applications SA, H1 2015 37
Peritoneal Cancer - Pipeline by Amgen Inc., H1 2015 38
Peritoneal Cancer - Pipeline by Astellas Pharma Inc., H1 2015 39
Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 40
Peritoneal Cancer - Pipeline by AstraZeneca PLC, H1 2015 41
Peritoneal Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2015 42
Peritoneal Cancer - Pipeline by Bayer AG, H1 2015 43
Peritoneal Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 44
Peritoneal Cancer - Pipeline by Bionomics Limited, H1 2015 45
Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 46
Peritoneal Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2015 47
Peritoneal Cancer - Pipeline by Celsion Corporation, H1 2015 48
Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 49
Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H1 2015 50
Peritoneal Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2015 51
Peritoneal Cancer - Pipeline by CritiTech, Inc., H1 2015 52
Peritoneal Cancer - Pipeline by CTI BioPharma Corp., H1 2015 53
Peritoneal Cancer - Pipeline by Eli Lilly and Company, H1 2015 54
Peritoneal Cancer - Pipeline by Exelixis, Inc., H1 2015 55
Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 56
Peritoneal Cancer - Pipeline by Galena Biopharma, Inc., H1 2015 57
Peritoneal Cancer - Pipeline by Genelux Corporation, H1 2015 58
Peritoneal Cancer - Pipeline by Genentech, Inc., H1 2015 59
Peritoneal Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 60
Peritoneal Cancer - Pipeline by Glycotope GmbH, H1 2015 61
Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H1 2015 62
Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H1 2015 63
Peritoneal Cancer - Pipeline by Immunotope, Inc., H1 2015 64
Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H1 2015 65
Peritoneal Cancer - Pipeline by Johnson & Johnson, H1 2015 66
Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 67
Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2015 68
Peritoneal Cancer - Pipeline by MedImmune, LLC, H1 2015 69
Peritoneal Cancer - Pipeline by Merck & Co., Inc., H1 2015 70
Peritoneal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 71
Peritoneal Cancer - Pipeline by NeoStem, Inc., H1 2015 72
Peritoneal Cancer - Pipeline by Novartis AG, H1 2015 73
Peritoneal Cancer - Pipeline by Neovii Biotech GmbH, H1 2015 74
Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2015 75
Peritoneal Cancer - Pipeline by OBI Pharma, Inc., H1 2015 76
Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H1 2015 77
Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2015 78
Peritoneal Cancer - Pipeline by Onxeo SA, H1 2015 79
Peritoneal Cancer - Pipeline by Oxford BioMedica plc, H1 2015 80
Peritoneal Cancer - Pipeline by OXiGENE, Inc., H1 2015 81
Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H1 2015 82
Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 83
Peritoneal Cancer - Pipeline by PsiOxus Therapeutics, Ltd., H1 2015 84
Peritoneal Cancer - Pipeline by Recepta Biopharma S.A., H1 2015 85
Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H1 2015 86
Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 87
Peritoneal Cancer - Pipeline by Takeda Oncology, H1 2015 88
Peritoneal Cancer - Pipeline by TapImmune Inc., H1 2015 89
Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H1 2015 90
Peritoneal Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 91
Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2015 92
Assessment by Monotherapy Products, H1 2015 93
Number of Products by Stage and Target, H1 2015 95
Number of Products by Stage and Mechanism of Action, H1 2015 100
Number of Products by Stage and Route of Administration, H1 2015 104
Number of Products by Stage and Molecule Type, H1 2015 106
Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 292
Peritoneal Cancer - Dormant Projects, H1 2015 432
Peritoneal Cancer - Discontinued Products, H1 2015 433

[List of Figures]
Number of Products under Development for Peritoneal Cancer, H1 2015 17
Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H1 2015 18
Number of Products under Development by Companies, H1 2015 19
Comparative Analysis by Late Stage Development, H1 2015 25
Comparative Analysis by Clinical Stage Development, H1 2015 26
Assessment by Monotherapy Products, H1 2015 93
Number of Products by Top 10 Targets, H1 2015 94
Number of Products by Stage and Top 10 Targets, H1 2015 94
Number of Products by Top 10 Mechanism of Actions, H1 2015 99
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 99
Number of Products by Top 10 Routes of Administration, H1 2015 103
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 103
Number of Products by Top 10 Molecule Types, H1 2015 105
Number of Products by Stage and Top 10 Molecule Types, H1 2015 105

【掲載企業】

AbbVie Inc.
Acceleron Pharma, Inc.
Adaptimmune Limited
Advanced Accelerator Applications SA
Amgen Inc.
Astellas Pharma Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca PLC
Basilea Pharmaceutica AG
Bayer AG
BioMarin Pharmaceutical Inc.
Bionomics Limited
Boehringer Ingelheim GmbH
Celldex Therapeutics, Inc.
Celsion Corporation
Cerulean Pharma, Inc.
Clovis Oncology, Inc.
Corcept Therapeutics Incorporated
CritiTech, Inc.
CTI BioPharma Corp.
Eli Lilly and Company
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Galena Biopharma, Inc.
Genelux Corporation
Genentech, Inc.
GlaxoSmithKline plc
Glycotope GmbH
Hemispherx Biopharma, Inc.
ImmunoGen, Inc.
Immunotope, Inc.
Immunovaccine, Inc.
Johnson & Johnson
Lee's Pharmaceutical Holdings Limited
MabVax Therapeutics Holdings, Inc.
MedImmune, LLC
Merck & Co., Inc.
Merrimack Pharmaceuticals, Inc.
NeoStem, Inc.
Novartis AG
Neovii Biotech GmbH
Oasmia Pharmaceutical AB
OBI Pharma, Inc.
Oncolytics Biotech Inc.
OncoMed Pharmaceuticals, Inc.
Onxeo SA
Oxford BioMedica plc
OXiGENE, Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
PsiOxus Therapeutics, Ltd.
Recepta Biopharma S.A.
Sanofi Pasteur SA
Synta Pharmaceuticals Corp.
Takeda Oncology
TapImmune Inc.
TetraLogic Pharmaceuticals
TRACON Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc.

★調査レポート[腹膜がん(Peritoneal Cancer)の治療薬パイプライン動向(2015年上半期版)] (コード:GMDHC6120IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[腹膜がん(Peritoneal Cancer)の治療薬パイプライン動向(2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆